TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03634579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Guided Focal Laser Interstitial Thermal Ablation
Description: The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps.
Study: NCT04280198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Parenting Videos
Description: Four video clips from the online Triple P Parenting program will be used to promote specific positive parenting practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Boxes
Description: There will be about 4 planned activities per week within activity boxes provided to families. The activities will be a context in which the positive parenting behaviors can be practiced. Each activity will take about 15 minutes. Families can pick each week whether they'd like their parenting practice to be embedded in reading activities, nature walks/active games, or arts and crafts. Instructions will be included with each activity, including prompts to allow the parent to apply learnings from that week's parenting video and to allow interactions to be child-led.
Study: NCT05809570

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examination
Description: A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient.
Study: NCT02262845

Intervention type: DEVICE
Intervention: The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Description: Used to drain pancreatic ducts

Intervention type: DEVICE
Intervention: The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Description: Used to drain pancreatic ducts

Intervention type: DEVICE
Intervention: The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Description: Used to drain pancreatic ducts

Intervention type: DEVICE
Intervention: The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Description: Used to drain pancreatic ducts

Intervention type: DEVICE
Intervention: The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
Description: Used to drain pancreatic ducts
Study: NCT01789944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Family-based behavioral intervention
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Family-based behavioral intervention
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
Study: NCT01927445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality improvement toolkit
Description: educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
Study: NCT03971617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: each hydrogen tablet contains 80mg magnesium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: matching placebo tablet
Study: NCT02925975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D-vHPS
Description: This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
Study: NCT01518985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia
Description: Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline (0.9%)
Description: Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Description: One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cigarette smoking
Description: One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
Study: NCT02925975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-vHPS
Description: This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D-vHPS
Description: This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-vHPS
Description: This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine endoscopic procedures
Description: These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine endoscopic procedures
Description: These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
Study: NCT03673436

Intervention type: PROCEDURE
Intervention: Lumbar spinal fusion
Description: The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
Study: NCT02411110

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
Study: NCT01253902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost ophthalmic solution 0.004%
Description: One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost ophthalmic solution 0.005%
Description: One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
Study: NCT02123264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid: 5 mg/year x 2 years
Study: NCT02411110

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: LiRIS Placebo
Description: LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
Study: NCT02157376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: iv esomeprazole 30 min intermittent infusions given for maximum 14 days
Study: NCT02565641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 mg/m\^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
Study: NCT01385059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy and pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy and pelvic lymph node dissection
Study: NCT02157376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Description: iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
Study: NCT01385059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03867331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 microgram VLPM01
Description: VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 microgram VLPM01
Description: VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 microgram VLPM01
Description: VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum challenge
Description: Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
Study: NCT01494285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARK-E021 5%
Description: Topically applied once daily at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARK-E021 10%
Description: Topically applied once daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically applied once daily at bedtime
Study: NCT02441452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early rehabilitation
Description: The physical exercises and breathing exercises are started as soon as after the Nuss procedure
Study: NCT03895060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autogenous ring blockls with GBR covered by collagen membrane
Description: * A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~* Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~* Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~* The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~* The flap will then be closed using interrupted 4/0 resorbable sutures.
Study: NCT04231630

Intervention type: OTHER
Group type: OTHER
Intervention: Prolacta
Description: Will receive outpatient supplementation with donor human milk product added to mother's own milk
Study: NCT00443547

Intervention type: DEVICE
Intervention: Vectra-T
Description: Patient will receive the Vectra-T plate (Sized 1 to 4 levels)

Intervention type: DEVICE
Intervention: Vectra-T
Description: Patient will receive the Vectra-T plate (Sized 1 to 4 levels)

Intervention type: DEVICE
Intervention: Vectra-T
Description: Patient will receive the Vectra-T plate (Sized 1 to 4 levels)

Intervention type: DEVICE
Intervention: Vectra-T
Description: Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
Study: NCT00983229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
Study: NCT03067441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempedoic acid
Description: bempedoic acid 180 mg tablets taken orally, once per day.
Study: NCT03814447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti- MESO CAR-T cells
Description: Autologous genetically modified anti- MESO CAR transduced T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose: 30mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose: 300mg/m2/d
Study: NCT02163031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: devices used in the coronary angiography
Description: devices used in coronary angiography by left or right radial route

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: devices used in the coronary angiography
Description: devices used in coronary angiography by left or right radial route
Study: NCT01226654

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging EDSS

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging EDSS
Study: NCT03564509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (1 μg) and follitropin delta
Description: Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (2 μg) and follitropin delta
Description: Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (4 μg) and follitropin delta
Description: Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (8 μg) and follitropin delta
Description: Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Study: NCT01465490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring and Feedback Intervention
Description: Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
Study: NCT02066935

Intervention type: OTHER
Intervention: kidney transplant patient
Description: kidney transplanted patients for at least one year
Study: NCT06535217

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study: NCT03866174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Set and Setting (SaS) Protocol
Description: The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Set and Setting (SaS) Protocol
Description: The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
Study: NCT02921412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: contact lens
Study: NCT02291718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue
Description: iodine contrast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue
Description: iodine contrast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue
Description: iodine contrast
Study: NCT02806739

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Group (Soy Protein + Isoflavones)
Description: Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (Minimize Soy Intake)
Description: Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
Study: NCT00882674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: 16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
Study: NCT01564225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDI200
Description: Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
Study: NCT03856424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 3
Description: High-flow oxygen
Study: NCT02842567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol plus Vitamin E
Description: This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
Study: NCT03613571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB
Description: The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
Study: NCT00521807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
Study: NCT02842567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
Study: NCT00395044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study: NCT03906058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
Study: NCT00987207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: a single bolus of 2.5 mg/kg, administered before aortic cross-declamping

Intervention type: OTHER
Group type: OTHER
Intervention: No injection
Description: No cyclosporine A is administered before aortic cross-declamping.
Study: NCT02506998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLE
Description: Adjuvant treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second generation anti histamines + Nasal corticosteroids
Description: Standard treatment
Study: NCT02446041

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT03564509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999302 (12 μg) and follitropin delta
Description: Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and follitropin delta
Description: Daily dose of placebo; individualized follitropin delta dose.
Study: NCT00591526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arac
Description: Ommit ARAC in the chemotherapy